Atlas Trials

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Clinical trial NCT04952597 · COMPLETED

Trial details

NCT number
NCT04952597
Sponsor
BeiGene
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Limited Stage Small Cell Lung Cancer
Start date
2021-07-15
Primary completion
2023-07-26
Enrollment
126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.